US major Honeywell (NASDAQ: HON) has announced a partnership with China-based Tonghua Anruite Biopharmaceutical Co., Ltd at the 5th China International Import Expo (CIIE). The collaboration aims to delve into smart manufacturing and digital transformation, focusing on building a digital innovation system to enhance the smart upgrade of pharmaceutical industry manufacturing. No financial details were disclosed.
Partnership Objectives
Honeywell will provide Anruite with the design and implementation of integrated solutions, including production process control (downstream process automatic control system of biopharmaceuticals), Trackwise quality management system (CAPA, OOT/OOS, Deviations), and GMP production network system. These solutions are designed to help Anruite build an advanced downstream production line for biopharmaceuticals (recombinant human albumin). The goal is to achieve production cost savings while improving capacity, optimizing production process operations, enhancing protein expression, and promoting continuous improvement in production processes.
Previous Collaboration
In April 2022, Honeywell signed a cooperation agreement to provide Anruite with a process automation system for the purification workshop in the first phase project of the recombinant human albumin production base. This initiative aimed to improve the digital level of all production factors, further solidifying the partnership’s commitment to advancing manufacturing efficiency and quality.
Anruite Profile
Founded in 2014, Anruite has completed a Phase II clinical study for its recombinant human albumin, demonstrating a good safety and efficacy profile. The company expects to conclude clinical trials within the next two years. The recombinant albumin industrial chemical plant under construction will produce 100 tons of recombinant human albumin upon full operation, meeting 15% of market demand.-Fineline Info & Tech
